144 related articles for article (PubMed ID: 12082641)
21. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
22. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
23. [Leukemogenesis by the AML1/EVI-1 chimeric protein].
Mitani K; Hirai H
Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):33-9. PubMed ID: 10643333
[No Abstract] [Full Text] [Related]
24. An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms.
Tanaka T; Tanaka K; Ogawa S; Kurokawa M; Mitani K; Yazaki Y; Shibata Y; Hirai H
Leukemia; 1997 Apr; 11 Suppl 3():299-302. PubMed ID: 9209372
[TBL] [Abstract][Full Text] [Related]
25. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
26. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
Adya N; Stacy T; Speck NA; Liu PP
Mol Cell Biol; 1998 Dec; 18(12):7432-43. PubMed ID: 9819429
[TBL] [Abstract][Full Text] [Related]
27. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
28. B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter.
Kamano H; Klempnauer KH
Oncogene; 1997 Mar; 14(10):1223-9. PubMed ID: 9121772
[TBL] [Abstract][Full Text] [Related]
29. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein.
Hromas R; Busse T; Carroll A; Mack D; Shopnick R; Zhang DE; Nakshatri H; Richkind K
Blood; 2001 Apr; 97(7):2168-70. PubMed ID: 11264187
[TBL] [Abstract][Full Text] [Related]
30. Expression of AML1-d, a short human AML1 isoform, in embryonic stem cells suppresses in vivo tumor growth and differentiation.
Aziz-Aloya RB; Levanon D; Karn H; Kidron D; Goldenberg D; Lotem J; Polak-Chaklon S; Groner Y
Cell Death Differ; 1998 Sep; 5(9):765-73. PubMed ID: 10200536
[TBL] [Abstract][Full Text] [Related]
31. Leukemogenesis by CBF oncoproteins.
Friedman AD
Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
[TBL] [Abstract][Full Text] [Related]
32. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Tahirov TH; Inoue-Bungo T; Morii H; Fujikawa A; Sasaki M; Kimura K; Shiina M; Sato K; Kumasaka T; Yamamoto M; Ishii S; Ogata K
Cell; 2001 Mar; 104(5):755-67. PubMed ID: 11257229
[TBL] [Abstract][Full Text] [Related]
33. Physical and functional link of the leukemia-associated factors AML1 and PML.
Nguyen LA; Pandolfi PP; Aikawa Y; Tagata Y; Ohki M; Kitabayashi I
Blood; 2005 Jan; 105(1):292-300. PubMed ID: 15331439
[TBL] [Abstract][Full Text] [Related]
34. Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene.
Cho JY; Akbarali Y; Zerbini LF; Gu X; Boltax J; Wang Y; Oettgen P; Zhang DE; Libermann TA
J Biol Chem; 2004 May; 279(19):19512-22. PubMed ID: 14970218
[TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.
Kanno Y; Kanno T; Sakakura C; Bae SC; Ito Y
Mol Cell Biol; 1998 Jul; 18(7):4252-61. PubMed ID: 9632809
[TBL] [Abstract][Full Text] [Related]
36. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.
Yamaguchi Y; Kurokawa M; Imai Y; Izutsu K; Asai T; Ichikawa M; Yamamoto G; Nitta E; Yamagata T; Sasaki K; Mitani K; Ogawa S; Chiba S; Hirai H
J Biol Chem; 2004 Apr; 279(15):15630-8. PubMed ID: 14752096
[TBL] [Abstract][Full Text] [Related]
37. The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding.
Bäckström S; Wolf-Watz M; Grundström C; Härd T; Grundström T; Sauer UH
J Mol Biol; 2002 Sep; 322(2):259-72. PubMed ID: 12217689
[TBL] [Abstract][Full Text] [Related]
38. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.
Peterson LF; Boyapati A; Ranganathan V; Iwama A; Tenen DG; Tsai S; Zhang DE
Mol Cell Biol; 2005 Dec; 25(23):10205-19. PubMed ID: 16287839
[TBL] [Abstract][Full Text] [Related]
39. Correlation between cellular localization of TEL/AML1 fusion protein and repression of AML1-mediated transactivation of CR1 gene.
Rho JK; Kim JH; Yu J; Choe SY
Biochem Biophys Res Commun; 2002 Sep; 297(1):91-5. PubMed ID: 12220513
[TBL] [Abstract][Full Text] [Related]
40. CCAAT/enhancer binding protein alpha uses distinct domains to prolong pituitary cells in the growth 1 and DNA synthesis phases of the cell cycle.
Liu W; Enwright JF; Hyun W; Day RN; Schaufele F
BMC Cell Biol; 2002 Mar; 3():6. PubMed ID: 11914124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
